Recent developments include the completion of the TransportNPC Phase 3 trial, submission of the NDA for Trappsol® Cyclo™, narrowing net losses in Q3 2026, and leadership transitions following the merger with Cyclo Therapeutics.

• Rafael submitted a New Drug Application to the FDA for Trappsol® Cyclo™ on October 28, 2026, following completion of the pivotal Phase 3 clinical trial [N1][S1].
• The Phase 3 trial did not meet its primary endpoint in the overall population but showed statistically significant benefit in a prespecified subgroup receiving background therapies [N1][N3][S1].
• The TransportNPC Phase 3 trial completed its final patient visit in June 2026 after enrolling 94 patients across 13 countries [N5][S1].
• Rafael reported narrowing net loss in Q3 2026 and noted stock price movement following the announcement [N4].
• The company announced leadership transition following the merger with Cyclo Therapeutics and full enrollment of the TransportNPC Phase 3 trial [N6][S1].
• Rafael continues to evaluate its portfolio companies and focus resources on Trappsol® Cyclo™ clinical development and commercialization [N6][S1].

Rafael Holdings has advanced its lead candidate Trappsol® Cyclo™ through a pivotal Phase 3 trial and submitted an NDA to the FDA, positioning it for potential regulatory approval in a rare disease with significant unmet need. The therapy's multiple FDA designations could provide market exclusivity and priority review benefits. The company’s diversified portfolio includes majority stakes in clinical and early-stage pharmaceutical and medical device companies, which may offer additional growth avenues. FDA clearance of the VECTR System by Rafael Medical Devices demonstrates regulatory progress in the medical device segment. Narrowing net losses and a solid liquidity position support ongoing development and commercialization efforts. Strategic leadership transitions and merger integrations indicate active portfolio management and focus on core assets.

The pivotal Phase 3 trial for Trappsol® Cyclo™ did not meet its primary endpoint in the overall population, which may complicate regulatory approval and commercial acceptance. The company reported a significant net loss of $29.6 million for fiscal 2026, reflecting ongoing development costs and limited revenue generation. Operations in some portfolio companies, such as Barer Institute, have been substantially curtailed, potentially limiting future pipeline contributions. The biotechnology sector's inherent risks, including clinical trial failures, regulatory delays, and market competition, pose challenges. Rafael's reliance on a single lead product candidate for near-term value and the need for successful FDA review introduce execution risks. The company's historical real estate holdings have largely been divested, reducing asset diversification.

Rafael Holdings' moat is primarily based on its proprietary cyclodextrin-based investigational therapy Trappsol® Cyclo™ for Niemann-Pick Disease Type C, a rare and fatal genetic disorder with high unmet medical need. The therapy has received multiple FDA designations including Orphan Drug, Fast Track, and Rare Pediatric Disease, which provide regulatory incentives and potential market exclusivity. The company also holds majority interests in several specialized portfolio companies in pharmaceuticals and medical devices, which may provide diversified innovation potential. However, the biotechnology sector's inherent risks, including clinical trial outcomes and regulatory approvals, affect the moat's durability. Rafael's FDA clearance for its orthopedic VECTR System adds a device-related competitive element. The company's focus on rare diseases and specialized technologies contributes to barriers to entry but depends heavily on successful clinical and regulatory execution.

• Clinical Trial Risk: The lead candidate Trappsol® Cyclo™ did not meet the primary endpoint in the overall Phase 3 trial population, which may affect regulatory approval and market acceptance.
• Regulatory Approval Risk: FDA review of the NDA will determine acceptance and potential priority review status; delays or rejection could impact commercialization.
• Financial Risk: The company reported a net loss of $29.6 million for fiscal 2026 and limited revenue, indicating ongoing funding needs and operational losses.
• Portfolio Concentration Risk: Operations in some portfolio companies have been curtailed, and the company is focused on a limited number of core assets, increasing dependency on successful execution of these.
• Market and Competitive Risk: The biotechnology and medical device sectors are highly competitive and subject to rapid technological and regulatory changes.

• Rafael Holdings, Inc. is a biotechnology company focused on developing pharmaceuticals and holding interests in clinical and early-stage pharmaceutical and medical device companies.
• The company's lead candidate is Trappsol® Cyclo™ (remibetadex), an investigational therapy for Niemann-Pick Disease Type C (NPC), a rare, fatal genetic disorder.
• Rafael completed the pivotal Phase 3 clinical trial of Trappsol® Cyclo™ and submitted a New Drug Application (NDA) to the FDA on October 28, 2026.
• The Phase 3 trial did not meet its primary endpoint in the overall population, but a prespecified analysis showed statistically significant treatment benefit in patients receiving background miglustat and/or leucine therapy.
• Trappsol® Cyclo™ has received FDA Fast Track designation, Orphan Drug designation in the US and Europe, and Rare Pediatric Disease designation.
• Rafael holds majority equity interests in several portfolio companies: LipoMedix Pharmaceuticals Ltd. (clinical stage pharmaceutical company), Barer Institute Inc. (early stage cancer assets, operations substantially curtailed), Cornerstone Pharmaceuticals, Inc. (cancer metabolism therapeutics), Rafael Medical Devices, LLC (orthopedic-focused medical device company), and Day Three Labs, Inc. (technology for third-party manufacturers).
• Rafael Medical Devices received FDA clearance for the VECTR System for minimally invasive ligament or fascia release surgeries.
• The company historically owned real estate assets but currently holds only a portion of a commercial building in Jerusalem, Israel.
• Financial snapshot as of July 31, 2026: cash and equivalents $22.1 million, current assets $25.8 million, current liabilities $11.0 million, current ratio 2.35, cash ratio 3.84.
• For fiscal year ended July 31, 2026, Rafael reported net loss of $29.6 million and basic and diluted EPS of -$0.58.
• Revenue for the quarter ended April 30, 2026 was $179,000.
• The company completed the TransportNPC Phase 3 trial with 94 patients across 13 countries, including a 2-year open-label extension.
• Rafael submitted the NDA including a request for a rare pediatric disease priority review voucher.
• Cyclo Therapeutics, LLC is a wholly owned subsidiary developing Trappsol® Cyclo™ and also operates a legacy fine chemical business.
• Rafael announced leadership transition following merger with Cyclo Therapeutics and full enrollment of the TransportNPC Phase 3 trial.
• Recent news includes reporting Phase 3 data, completion of final patient visit in the trial, narrowing net loss in Q3, and the NDA submission.
• The company continues to evaluate its portfolio and focus resources on Trappsol® Cyclo™ clinical development and commercialization efforts.